Zacks Research Weighs in on Glaukos FY2028 Earnings

Glaukos Corporation (NYSE:GKOS) – Investment analysts at Zacks Research issued their FY2028 earnings per share estimates for Glaukos in a note issued to investors on Monday, March 9th. Zacks Research analyst Team anticipates that the medical instruments supplier will post earnings per share of $1.68 for the year. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share.

Several other brokerages also recently issued reports on GKOS. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. UBS Group boosted their price objective on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a research note on Wednesday, January 14th. Truist Financial increased their target price on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Wells Fargo & Company lifted their price target on Glaukos from $122.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.69.

Glaukos Stock Performance

Shares of GKOS stock opened at $105.60 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. Glaukos has a 52 week low of $73.16 and a 52 week high of $130.23. The company’s 50 day moving average price is $115.63 and its two-hundred day moving average price is $101.12. The company has a market capitalization of $6.13 billion, a P/E ratio of -32.39 and a beta of 0.70.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The business had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. During the same quarter last year, the firm earned ($0.40) EPS. The company’s revenue for the quarter was up 35.6% on a year-over-year basis.

Insider Buying and Selling at Glaukos

In related news, COO Joseph E. Gilliam sold 10,498 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total value of $1,340,384.64. Following the completion of the transaction, the chief operating officer owned 92,366 shares of the company’s stock, valued at approximately $11,793,290.88. This trade represents a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the completion of the sale, the director owned 37,449 shares in the company, valued at $4,782,611.79. The trade was a 28.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 320,000 shares of company stock worth $37,202,909. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

A number of large investors have recently modified their holdings of the business. Smartleaf Asset Management LLC grew its holdings in shares of Glaukos by 9.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after acquiring an additional 122 shares in the last quarter. Larson Financial Group LLC raised its holdings in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 132 shares in the last quarter. CWM LLC boosted its position in Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 143 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Glaukos by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after purchasing an additional 144 shares in the last quarter. Finally, Evergreen Capital Management LLC grew its stake in Glaukos by 4.3% in the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 145 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.